DUBLIN--(BUSINESS WIRE)--
ICON
plc, (NASDAQ: ICLR) (ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, commenced direct trading of
ICON ordinary shares on NASDAQ (CUSIP Number G4705A 100) yesterday, 4th
February 2013. This follows ICON's withdrawal from the Irish Stock
Exchange on the 30th January 2013 and the termination of the
ADR programme in accordance with the resolutions approved by the
shareholders at the Extraordinary General Meeting of the Company on 17th
December 2012.
The information contained in this release is as of 5th
February 2013. The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to ICON
and its business can be found in ICON's
Annual Report for the fiscal year ended December 31, 2011 and in the
forms filed with the US
Securities and Exchange Commission, including the Forms 20-F, F-1,
S-8 and F-3. ICON disclaims any intent or obligation to update these
forward-looking statements.
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries. The
company specialises in the strategic development, management and
analysis of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in Dublin,
Ireland, ICON currently, operates from 82 locations in 40 countries and
has approximately 9,430 employees. Further information is available at http://www.iconplc.com.
ICON/ICLR-F
ICON
Investor Relations
1-888-381-7923
or
Brendan
Brennan
Chief Financial Officer
+ 353 —1-291-2000
or
Sam
Farthing
VP Investor Relations
+ 353 —1-291-2000
Source: ICON plc
News Provided by Acquire Media
